Spruce Biosciences Inc. (SPRB) that reached significant study milestones last year, anticipates a year filled with key catalysts in 2024.
This clinical-stage biopharmaceutical company is developing novel therapies for rare endocrine disorders with significant unmet medical need. The lead drug candidate is Tildacerfont, being developed for patients with classic congenital adrenal hyperplasia (CAH) and other diseases characterized by elevated levels of adrenocorticotropic hormone (ACTH).
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.